Bank of America company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The lender’s CEO said the bank’s medication benefit costs are climbing, but he framed the spending as an investment in employee health and retention.
THE APEX TIMES
THE APEX TIMES
The company’s CEO, Brian Moynihan, characterized the benefit as an investment in workforce health and productivity, citing a large annual spend on GLP-1 medications such as Ozempic.
THE APEX TIMES
A Bank of America strategist says investor optimism has moved to its most extreme bullish level since 2021, arguing that riskier positions may warrant a reduction.
THE APEX TIMES
A fresh disclosure focused on anti-money laundering deficiencies has brought regulatory penalty risk back into the spotlight for Bank of America’s stock, putting investors on notice to watch for further developments.
THE APEX TIMES
A post on Yahoo Finance says Bank of America is “doubling down” on SpaceX following earnings-driven volatility, as investors weighed a quarter marked by higher capital expenditures and lingering concerns about cash generation.
THE APEX TIMES
Bank of America lowered its Uber Technologies price target to $101 from $103 while maintaining a Buy rating, citing a still-improving earnings outlook following the company’s second-quarter results, according to a report published by Proactive Investors.
THE APEX TIMES
The bank pointed to rising prices and utilization of GLP-1 weight-loss drugs, saying the benefits for employee health still justify the spend.
THE APEX TIMES
CEO Brian Moynihan said the bank expects some employees to leave before they can benefit from the health program, even as it continues to cover costly GLP-1 medications.
THE APEX TIMES
In a CNBC interview, the bank’s CEO said inflation had been cooling before pressures tied to tariffs and pricing effects resurfaced, though he expects those factors to begin to fade.
